US FDA grants approval for Novartis' Ilaris to treat Periodic Fever Syndromes
Novartis received approval to market its Periodic Fever Syndrome drug Ilaris (cancakinumab). The drug targets the syndrome, and will be used to treat a group of diseases that cause serious recurrent fever and pathogenic inflammation through non-infectious activation of the immune system. Ilaris inhibits Interleukin-1 (IL-1) beta, and is already approved in the US to treat Cryopyrin-Associated Periodic Syndromes (CAPS) and Systemic Juvenile Idiopathic Arthritis (SJIA).
Sanaria receives FDA fast-track designation for malaria vaccine
PfSPZ, the malaria vaccine of Sanaria, has received fast-trac...
